logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
7/26/2018 4:04:22 PM Seattle Genetics Q2 EPS $0.47 Vs Loss $0.39 Last Year
7/12/2018 8:01:23 AM Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Of Tisotumab Vedotin
7/11/2018 8:02:02 AM Seattle Genetics Publishes Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer
6/29/2018 10:22:26 AM Genmab To Pay Seattle Genetics Milestone Payment Of $7 Mln Under Antibody-Drug Conjugate Program Targeting AXL
6/26/2018 8:02:00 AM BioClin Therapeutics Appoints Scott Myers As Chairman
6/13/2018 8:02:37 AM Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin
6/4/2018 9:05:05 AM Seattle Highlights Addl Analyses From Phase 3 ECHELON-1 Trial Of ADCETRIS In Newly Diagnosed Advanced Hodgkin Lymphoma
5/17/2018 9:05:59 AM Seattle Genetics Appoints Roger Dansey As Chief Medical Officer
4/26/2018 4:05:00 PM Seattle Genetics Q1 Loss/share $0.73 Vs. Loss $0.42 Year Ago
4/12/2018 8:05:19 AM Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies And Immuno-Oncology Program Advances At AACR
3/26/2018 8:03:16 AM Astellas, Seattle Genetics Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
3/26/2018 8:02:01 AM Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin